Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease

Cell

Volumn 167, Issue 3, 2016, Pages 843-857.e14

  Finan, Brian ^a,b,c   Clemmensen, Christoffer ^a,b,c   Zhu, Zhimeng ^d   Stemmer, Kerstin ^a,b,c   Gauthier, Karine ^e   Müller, Luisa ^a   De Angelis, Meri ^a   Moreth, Kristin ^a   Neff, Frauke ^a   Perez Tilve, Diego ^f   Fischer, Katrin ^a,b   Lutter, Dominik ^a,b,c   Sánchez Garrido, Miguel A ^a,b   Liu, Peng ^g   Tuckermann, Jan ^g   Malehmir, Mohsen ^h   Healy, Marc E ^h   Weber, Achim ^h   Heikenwalder, Mathias ^b,i   Jastroch, Martin ^a,b   Kleinert, Maximilian ^a,b,n   Jall, Sigrid ^a,b   Brandt, Sara ^a,b   Flamant, Frédéric ^e   Schramm, Karl Werner ^a   Biebermann, Heike ^j   Döring, Yvonne ^k,o   Weber, Christian ^k,p   Habegger, Kirk M ^l   Keuper, Michaela ^a   Gelfanov, Vasily ^d   Liu, Fa ^m   Köhrle, Josef ^j   Rozman, Jan ^a,c   Fuchs, Helmut ^a   Gailus Durner, Valerie ^a   Hrabě de Angelis, Martin ^a,b,c   Hofmann, Susanna M ^a,c,k   Yang, Bin ^d   Tschöp, Matthias H ^a,b,c   DiMarchi, Richard ^d   Müller, Timo D ^a,b,c   more..

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITÉ DE LYON   (France)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF ULM   (Germany)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l University of Alabama at Birmingham   (United States)

^m Calibrium LLC   (United States)

ⁿ UNIVERSITY OF COPENHAGEN   (Denmark)

^o DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^p MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

co agonist; conjugate; dyslipidemia; glucagon; NASH; obesity; polypharmacology; thyroid hormone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCAGON; GLUCAGON DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; THYROID HORMONE; TRIACYLGLYCEROL; DRUG COMBINATION; LIOTHYRONINE;

ADIPOCYTE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BODY WEIGHT; BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HALF LIFE; ENERGY EXPENDITURE; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYBRIDIZATION; HYPERLIPIDEMIA; LIPID METABOLISM; LIVER CELL; LONG TERM CARE; MALE; MASS SPECTROMETRY; METABOLIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; THERMOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BONE; CHEMICAL ENGINEERING; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG POTENTIATION; HYPERGLYCEMIA; LIVER; METABOLIC DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PROCEDURES;

ANIMALS; ATHEROSCLEROSIS; BODY WEIGHT; BONE AND BONES; CHEMICAL ENGINEERING; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; GLUCAGON; HYPERGLYCEMIA; LIVER; METABOLIC DISEASES; MICE; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; TRIIODOTHYRONINE;

EID: 84992036608     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.09.014     Document Type: Article

References (52)

1. Baxter, J.D., Webb, P., Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat. Rev. Drug Discov. 8 (2009), 308–320.
2. Bianco, A.C., Silva, J.E., Intracellular conversion of thyroxine to triiodothyronine is required for the optimal thermogenic function of brown adipose tissue. J. Clin. Invest. 79 (1987), 295–300.
3. Billington, C.J., Briggs, J.E., Link, J.G., Levine, A.S., Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo. Am. J. Physiol. 261 (1991), R501–R507.
4. Billon, C., Canaple, L., Fleury, S., Deloire, A., Beylot, M., Dombrowicz, D., Del Carmine, P., Samarut, J., Gauthier, K., TRalpha protects against atherosclerosis in male mice: identification of a novel anti-inflammatory property for TRalpha in mice. Endocrinology 155 (2014), 2735–2745.
5. Burcelin, R., Li, J., Charron, M.J., Cloning and sequence analysis of the murine glucagon receptor-encoding gene. Gene 164 (1995), 305–310.
6. Day, J.W., Ottaway, N., Patterson, J.T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D.J., Chaudhary, N., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5 (2009), 749–757.
7. Diamond, D.M., Ravnskov, U., How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Rev. Clin. Pharmacol. 8 (2015), 201–210.
8. Dicker, A., Zhao, J., Cannon, B., Nedergaard, J., Apparent thermogenic effect of injected glucagon is not due to a direct effect on brown fat cells. Am. J. Physiol. 275 (1998), R1674–R1682.
9. Domouzoglou, E.M., Fisher, F.M., Astapova, I., Fox, E.C., Kharitonenkov, A., Flier, J.S., Hollenberg, A.N., Maratos-Flier, E., Fibroblast growth factor 21 and thyroid hormone show mutual regulatory dependency but have independent actions in vivo. Endocrinology 155 (2014), 2031–2040.
10. Finan, B., Yang, B., Ottaway, N., Stemmer, K., Müller, T.D., Yi, C.X., Habegger, K., Schriever, S.C., García-Cáceres, C., Kabra, D.G., et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18 (2012), 1847–1856.
11. Finan, B., Ma, T., Ottaway, N., Müller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med., 5, 2013, 209ra151.
12. Finan, B., Yang, B., Ottaway, N., Smiley, D.L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K.M., Fischer, K., et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21 (2015), 27–36.
13. Finck, B.N., Kelly, D.P., PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 116 (2006), 615–622.
14. Fisher, F.M., Estall, J.L., Adams, A.C., Antonellis, P.J., Bina, H.A., Flier, J.S., Kharitonenkov, A., Spiegelman, B.M., Maratos-Flier, E., Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152 (2011), 2996–3004.
15. Gaich, G., Chien, J.Y., Fu, H., Glass, L.C., Deeg, M.A., Holland, W.L., Kharitonenkov, A., Bumol, T., Schilske, H.K., Moller, D.E., The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18 (2013), 333–340.
16. Grover, G.J., Mellström, K., Ye, L., Malm, J., Li, Y.L., Bladh, L.G., Sleph, P.G., Smith, M.A., George, R., Vennström, B., et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc. Natl. Acad. Sci. USA 100 (2003), 10067–10072.
17. Habegger, K.M., Heppner, K.M., Geary, N., Bartness, T.J., DiMarchi, R., Tschöp, M.H., The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 6 (2010), 689–697.
18. Habegger, K.M., Stemmer, K., Cheng, C., Müller, T.D., Heppner, K.M., Ottaway, N., Holland, J., Hembree, J.L., Smiley, D., Gelfanov, V., et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62 (2013), 1453–1463.
19. Herzig, S., Long, F., Jhala, U.S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413 (2001), 179–183.
20. Hotta, Y., Nakamura, H., Konishi, M., Murata, Y., Takagi, H., Matsumura, S., Inoue, K., Fushiki, T., Itoh, N., Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150 (2009), 4625–4633.
21. Kellendonk, C., Opherk, C., Anlag, K., Schutz, G., Tronche, F., Hepatocyte-specific expression of Cre recombinase. Genesis 26 (2000), 151–153.
22. Kelly, M.J., Pietranico-Cole, S., Larigan, J.D., Haynes, N.E., Reynolds, C.H., Scott, N., Vermeulen, J., Dvorozniak, M., Conde-Knape, K., Huang, K.S., et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia. J. Med. Chem. 57 (2014), 3912–3923.
23. Kharitonenkov, A., Adams, A.C., Inventing new medicines: the FGF21 story. Mol. Metab. 3 (2013), 221–229.
24. Kong, W.M., Martin, N.M., Smith, K.L., Gardiner, J.V., Connoley, I.P., Stephens, D.A., Dhillo, W.S., Ghatei, M.A., Small, C.J., Bloom, S.R., Triiodothyronine stimulates food intake via the hypothalamic ventromedial nucleus independent of changes in energy expenditure. Endocrinology 145 (2004), 5252–5258.
25. Ladenson, P.W., McCarren, M., Morkin, E., Edson, R.G., Shih, M.C., Warren, S.R., Barnhill, J.G., Churby, L., Thai, H., O'Brien, T., et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J. Clin. Endocrinol. Metab. 95 (2010), 1349–1354.
26. Lin, J., Handschin, C., Spiegelman, B.M., Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1 (2005), 361–370.
27. Lin, J.Z., Martagón, A.J., Hsueh, W.A., Baxter, J.D., Gustafsson, J.A., Webb, P., Phillips, K.J., Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 153 (2012), 6136–6144.
28. Lin, J.Z., Martagón, A.J., Cimini, S.L., Gonzalez, D.D., Tinkey, D.W., Biter, A., Baxter, J.D., Webb, P., Gustafsson, J.A., Hartig, S.M., Phillips, K.J., Pharmacological activation of thyroid hormone receptors elicits a functional conversion of white to brown fat. Cell Rep. 13 (2015), 1528–1537.
29. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 2014, 550.
30. Morreale de Escobar, G., Pastor, R., Obregon, M.J., Escobar del Rey, F., Effects of maternal hypothyroidism on the weight and thyroid hormone content of rat embryonic tissues, before and after onset of fetal thyroid function. Endocrinology 117 (1985), 1890–1900.
31. Mullur, R., Liu, Y.Y., Brent, G.A., Thyroid hormone regulation of metabolism. Physiol. Rev. 94 (2014), 355–382.
32. Nicholls, S.J., Ballantyne, C.M., Barter, P.J., Chapman, M.J., Erbel, R.M., Libby, P., Raichlen, J.S., Uno, K., Borgman, M., Wolski, K., Nissen, S.E., Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 365 (2011), 2078–2087.
33. Ochs, N., Auer, R., Bauer, D.C., Nanchen, D., Gussekloo, J., Cornuz, J., Rodondi, N., Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann. Intern. Med. 148 (2008), 832–845.
34. Penhos, J.C., Wu, C.H., Daunas, J., Reitman, M., Levine, R., Effect of glucagon on the metabolism of lipids and on urea formation by the perfused rat liver. Diabetes 15 (1966), 740–748.
35. Perry, R.J., Kim, T., Zhang, X.M., Lee, H.Y., Pesta, D., Popov, V.B., Zhang, D., Rahimi, Y., Jurczak, M.J., Cline, G.W., et al. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metab. 18 (2013), 740–748.
36. Planavila, A., Redondo, I., Hondares, E., Vinciguerra, M., Munts, C., Iglesias, R., Gabrielli, L.A., Sitges, M., Giralt, M., van Bilsen, M., Villarroya, F., Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun., 4, 2013, 2019.
37. Samms, R.J., Smith, D.P., Cheng, C.C., Antonellis, P.P., Perfield, J.W. 2nd, Kharitonenkov, A., Gimeno, R.E., Adams, A.C., Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep. 11 (2015), 991–999.
38. Schwenger, K.J., Allard, J.P., Clinical approaches to non-alcoholic fatty liver disease. World J. Gastroenterol. 20 (2014), 1712–1723.
39. Schwenk, R.W., Baumeier, C., Finan, B., Kluth, O., Brauer, C., Joost, H.G., DiMarchi, R.D., Tschöp, M.H., Schürmann, A., GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia 58 (2015), 604–614.
40. Selmi-Ruby, S., Bouazza, L., Obregon, M.J., Conscience, A., Flamant, F., Samarut, J., Borson-Chazot, F., Rousset, B., The targeted inactivation of TRbeta gene in thyroid follicular cells suggests a new mechanism of regulation of thyroid hormone production. Endocrinology 155 (2014), 635–646.
41. Silva, J.E., Thermogenic mechanisms and their hormonal regulation. Physiol. Rev. 86 (2006), 435–464.
42. Sinha, R.A., You, S.H., Zhou, J., Siddique, M.M., Bay, B.H., Zhu, X., Privalsky, M.L., Cheng, S.Y., Stevens, R.D., Summers, S.A., et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J. Clin. Invest. 122 (2012), 2428–2438.
43. Sinha, R.A., Singh, B.K., Yen, P.M., Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. Trends Endocrinol. Metab. 25 (2014), 538–545.
44. Sjouke, B., Langslet, G., Ceska, R., Nicholls, S.J., Nissen, S.E., Öhlander, M., Ladenson, P.W., Olsson, A.G., Hovingh, G.K., Kastelein, J.J., Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol. 2 (2014), 455–463.
45. Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B.M., et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23 (2016), 427–440.
46. Taub, R., Chiang, E., Chabot-Blanchet, M., Kelly, M.J., Reeves, R.A., Guertin, M.C., Tardif, J.C., Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis 230 (2013), 373–380.
47. Tiano, J.P., Tate, C.R., Yang, B.S., DiMarchi, R., Mauvais-Jarvis, F., Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis. Sci. Rep., 5, 2015, 10211.
48. Véniant, M.M., Sivits, G., Helmering, J., Komorowski, R., Lee, J., Fan, W., Moyer, C., Lloyd, D.J., Pharmacologic effects of FGF21 are independent of the “browning” of white adipose tissue. Cell Metab. 21 (2015), 731–738.
49. Wagner, R.L., Huber, B.R., Shiau, A.K., Kelly, A., Cunha Lima, S.T., Scanlan, T.S., Apriletti, J.W., Baxter, J.D., West, B.L., Fletterick, R.J., Hormone selectivity in thyroid hormone receptors. Mol. Endocrinol. 15 (2001), 398–410.
50. Wang, X., Wei, W., Krzeszinski, J.Y., Wang, Y., Wan, Y., A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption. Cell Metab. 22 (2015), 811–824.
51. Wei, W., Dutchak, P.A., Wang, X., Ding, X., Wang, X., Bookout, A.L., Goetz, R., Mohammadi, M., Gerard, R.D., Dechow, P.C., et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc. Natl. Acad. Sci. USA 109 (2012), 3143–3148.
52. Wolf, M.J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26 (2014), 549–564.